On Wednesday, Motorola Solutions Inc (NYSE:MSI)’s shares inclined 6.34% to $64.04.
Motorola Solutions (MSI), the leading global provider of innovative mission-critical communications solutions for public safety and commercial customers, recently declared that Silver Lake, the global leader in technology investing, will make a $1 billion investment in Motorola Solutions. The company anticipates to use the Silver Lake investment to accelerate growth in its smart public safety solutions and services businesses through new partnerships, investments and acquisitions.
Motorola Solutions, Inc. provides mission-critical communication infrastructure, devices, software, and services in North America, Latin America, the Asia Pacific, the Middle East, Europe, and Africa. The company operates in two segments, Products and Services. The Products segment offers a portfolio of network infrastructure, devices, accessories, and software for government, public safety and first-responder agencies, municipalities, and commercial and industrial customers.
Array Biopharma Inc (NASDAQ:ARRY)’s shares gained 4.99% to $6.10.
Array BioPharma Inc. (ARRY) stated results for the fourth quarter and full year of its fiscal year ended June 30, 2015.
Ron Squarer, Chief Executive Officer of Array, noted, “Binimetinib and encorafenib, two innovative oncology products in Phase 3, are on track for regulatory submissions in 2016. Additional data shared over the summer in BRAF-mutant melanoma and BRAF-mutant colorectal cancer further validate the value of these programs by showing the potential for differentiation contrast to other approaches. Binimetinib and encorafenib have accelerated our path to commercialization and provide us with opportunities to test these broadly active products across a number of indications.”
Array ended the quarter with $185.1 million in cash, cash equivalents, marketable securities and accounts receivable. Accounts receivable as of June 30, 2015 primarily comprises of current receivables predictable to be repaid by Novartis within three months. Revenue for the fourth quarter of fiscal 2015 was $12.3 million, contrast to $6.0 million for the same period last year. The $6.3 million enhance in revenue from the preceding period was primarily due to $5.7 million in reimbursable research and development expenses from Novartis. Cost of partnered programs for the fourth quarter of fiscal 2015 was $7.0 million, contrast to $11.4 million for the same period last year. Research and development expense was $18.6 million, contrast to $14.5 million in the same preceding year period. The enhance in research and development expense and corresponding decrease in cost of partnered programs is related to binimetinib and encorafenib being recently classified in research and development for the last three months of the fiscal year, rather than in the cost of partnered programs. Net loss for the fourth quarter was $12.7 million, or ($0.09) per share (diluted), and was $28.2 million, or ($0.22) per share (diluted), for the same period in fiscal 2014.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial comprise ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease.
At the end of Wednesday’s trade, Union Pacific Corporation (NYSE:UNP)‘s shares dipped -0.68% to $95.07.
Union Pacific was named among the Best Employers for Healthy Lifestyles for 2015 by The National Business Group on Health (NBGH).
Recognized at the gold level, Union Pacific was honored for making cultural and environmental changes, and developing comprehensive programs that support employees’ healthy lifestyle aims. The company was the only railroad among 64 U.S. employers to receive the 2015 Best Employers for Healthy Lifestyles® award.
The railroad’s wellness programs assess and provide intervention support for health risk factors, counting asthma, blood pressure, cholesterol, depression, diabetes, fatigue, inactivity, nutrition, smoking, stress and weight.
Union Pacific Corporation, through its partner, Union Pacific Railroad Company, operates railroads in the United States. The company offers freight transportation services for agricultural products, counting grains, commodities produced from grains, and food and beverage products; automotive products, such as finished vehicles and automotive parts; and chemicals compriseing of industrial chemicals, plastics, crude oil, liquid petroleum gases, fertilizers, soda ash, sodium products, and phosphorus rock and sulfur products.
Noble Energy, Inc. (NYSE:NBL), ended its Wednesday’s trading session with -1.79% loss, and closed at $33.41.
CONE Midstream Partners LP (CNNX) stated financial and operational results for the three months ending June 30, 2015.(1)
Second Quarter Results
Highlights of second quarter 2015 results attributable to the Partnership comprise:
- Net income of $14.9 million
- Average daily throughput volumes of 568 billion Btu per day (BBtu/d)
- EBITDA(2)of $17.0 million
- Distributable cash flow (DCF)(2)of $14.8 million
Noble Energy, Inc., an independent energy company, engages in the acquisition, exploration, and production of crude oil, natural gas, and natural gas liquids worldwide. Its principal projects are located in onshore DJ Basin and Marcellus Shale, the United States; the deepwater Gulf of Mexico; offshore West Africa; and offshore Eastern Mediterranean.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
